Skip to main content
Advertisement
Advertisement

NKTX

NKTX logo

Nkarta, Inc. Common Stock

2.75
USD
Sponsored
-0.10
-3.51%
Sep 25, 15:59 UTC -4
Closed
exchange

After-Market

2.75

0.00
+0.04%

NKTX Earnings Reports

Positive Surprise Ratio

NKTX beat 13 of 25 last estimates.

52%

Next Report

Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.42
Implied change from Q2 26 (Revenue/ EPS)
--
/
-22.22%
Implied change from Q3 25 (Revenue/ EPS)
--
/
+50.00%

Nkarta, Inc. Common Stock earnings per share and revenue

On Aug 10, 2026, NKTX reported earnings of -0.54 USD per share (EPS) for Q2 26, missing the estimate of -0.38 USD, resulting in a -40.81% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -5.28% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.42 USD, with revenue projected to reach -- USD, implying an decrease of -22.22% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
logo
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
logo
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
logo
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
logo
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
logo
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
logo
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
logo
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
For Q2 2026, Nkarta, Inc. Common Stock reported EPS of -$0.54, missing estimates by -40.81%, and revenue of $0.00, 0% as expectations.
The stock price moved down -5.28%, changed from $2.46 before the earnings release to $2.33 the day after.
The next earning report is scheduled for Nov 09, 2026.
Based on 6 analysts, Nkarta, Inc. Common Stock is expected to report EPS of -$0.42 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement